Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in: Experimental Hematology & Oncology 1/2012

Open Access 01-12-2012 | Letter to the Editor

Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma

Authors: Guoqing Wei, Uzoma Nwakuche, Gustavo Cadavid, Asim Ajaz, Karen Seiter, Delong Liu

Published in: Experimental Hematology & Oncology | Issue 1/2012

Login to get access

Excerpt

To the editor …
Literature
1.
2.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010,363(8):711–723. 10.1056/NEJMoa1003466PubMedCentralPubMedCrossRef
3.
Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, Arellano ML: Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009,32(3):322–324. 10.1097/CJI.0b013e31819aa40bPubMedCrossRef
Metadata
Title
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Authors
Guoqing Wei
Uzoma Nwakuche
Gustavo Cadavid
Asim Ajaz
Karen Seiter
Delong Liu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2012
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/2162-3619-1-3

Other articles of this Issue 1/2012

Experimental Hematology & Oncology 1/2012 Go to the issue

Short report

Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody

Review

Roles of Polo-like kinase 3 in suppressing tumor angiogenesis

Review

The role of BCL11B in hematological malignancy

Case report

Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation

Review

Digitoxin and its analogs as novel cancer therapeutics

Review

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits